Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use

Authors

Languages

Publication year

2025

Type

Tags

Mpox-Policy

This resource appears in the following Hot Topic page:

The resource is included in the following table:

Title	Author	Year	Type	Language
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age	European Medicines Agency	2024	Guidance	English
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response	World Health Organization (WHO)	2025	Guidance	English
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim Guidance	World Health Organization (WHO)	2025	Guidance	English, French
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidance	World Health Organization (WHO)	2024	Guidance	English, French
Off-label vaccine use: explanatory note for countries	World Health Organization (WHO)	2024	Guidance	English
Regulatory & Policy Considerations for Mpox Vaccines in African Countries	World Health Organization (WHO), European Medicines Agency, Bavarian Nordic	2025	Presentation	English
Smallpox and mpox (orthopoxviruses): WHO position paper	World Health Organization (WHO)	2024	Guidance	English, French
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use	World Health Organization (WHO)	2025	Presentation	English

Mpox-Policy-FR

The resource is included in the following table:

Title	Author	Year	Type	Language
Vaccin contre la variole et la mpox MVA-BN (‎Modified Vaccinia Ankara - Bavarian Nordic)‎ : directives provisoires	World Health Organization (WHO)	2024	Guidance	French, English
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age	European Medicines Agency	2024	Guidance	English
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response	World Health Organization (WHO)	2025	Guidance	English
Note de synthèse: position de l’OMS sur les vaccins contre la variole et la mpox (orthopoxvirus)	World Health Organization (WHO)	2024	Guidance	French, English
Off-label vaccine use: explanatory note for countries	World Health Organization (WHO)	2024	Guidance	English
Regulatory & Policy Considerations for Mpox Vaccines in African Countries	World Health Organization (WHO), European Medicines Agency, Bavarian Nordic	2025	Presentation	English
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use	World Health Organization (WHO)	2025	Presentation	English
Vaccin LC16m8 (‎vaccin lyophilisé vivant atténué)‎ contre la variole et la variole du singe : directives provisoires	World Health Organization (WHO)	2025	Guidance	French, English

Added on: 2024-11-19 15:06:01

Presentation